FR3061660B1 - Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide - Google Patents

Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide Download PDF

Info

Publication number
FR3061660B1
FR3061660B1 FR1750221A FR1750221A FR3061660B1 FR 3061660 B1 FR3061660 B1 FR 3061660B1 FR 1750221 A FR1750221 A FR 1750221A FR 1750221 A FR1750221 A FR 1750221A FR 3061660 B1 FR3061660 B1 FR 3061660B1
Authority
FR
France
Prior art keywords
compositions
aqueous solution
polyaminoacid
human glucagon
injection aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1750221A
Other languages
English (en)
Other versions
FR3061660A1 (fr
Inventor
Alexandre GEISSLER
Segolene Laage
Olivier Soula
David Duracher
Gregory Meiffren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1750221A priority Critical patent/FR3061660B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to BR112018075259-2A priority patent/BR112018075259A2/pt
Priority to EP17728541.8A priority patent/EP3463294B1/fr
Priority to CA3026802A priority patent/CA3026802A1/fr
Priority to CA3027238A priority patent/CA3027238A1/fr
Priority to PCT/EP2017/063887 priority patent/WO2017211917A1/fr
Priority to PCT/EP2017/063888 priority patent/WO2017211918A1/fr
Priority to CN201780049290.0A priority patent/CN109562064A/zh
Priority to EP17728542.6A priority patent/EP3463295B1/fr
Priority to BR112018075250-9A priority patent/BR112018075250A2/pt
Priority to JP2018564218A priority patent/JP2019521107A/ja
Priority to KR1020197000540A priority patent/KR20190025905A/ko
Priority to JP2018564397A priority patent/JP2019517560A/ja
Priority to MX2018015069A priority patent/MX2018015069A/es
Priority to SG11201810939PA priority patent/SG11201810939PA/en
Priority to MX2018015070A priority patent/MX2018015070A/es
Priority to US15/616,627 priority patent/US10485851B2/en
Priority to SG11201810901VA priority patent/SG11201810901VA/en
Priority to US15/616,542 priority patent/US10383918B2/en
Priority to KR1020197000533A priority patent/KR20190026748A/ko
Priority to CN201780047755.9A priority patent/CN109562063A/zh
Priority to AU2017277590A priority patent/AU2017277590A1/en
Priority to AU2017277589A priority patent/AU2017277589A1/en
Publication of FR3061660A1 publication Critical patent/FR3061660A1/fr
Publication of FR3061660B1 publication Critical patent/FR3061660B1/fr
Application granted granted Critical
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

[0001] L'invention concerne ainsi des compositions stables physiquement sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : a) du glucagon humain et b) un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Hy, [0002] Dans un mode de réalisation, les compositions selon l'invention comprennent en outre une hormone gastrointestinale.
FR1750221A 2016-06-07 2017-01-10 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide Expired - Fee Related FR3061660B1 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
FR1750221A FR3061660B1 (fr) 2017-01-10 2017-01-10 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
CN201780047755.9A CN109562063A (zh) 2016-06-07 2017-06-07 包含人胰高血糖素和末端接枝的共聚氨基酸的可注射水溶液形式的组合物
MX2018015069A MX2018015069A (es) 2016-06-07 2017-06-07 Composiciones bajo la forma de solución acuosa inyectable que comprende glucagón humano y co-poliaminoacido estadístico.
CA3027238A CA3027238A1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
PCT/EP2017/063887 WO2017211917A1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
PCT/EP2017/063888 WO2017211918A1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacidegreffe en bout de chaine
CN201780049290.0A CN109562064A (zh) 2016-06-07 2017-06-07 包含人胰高血糖素和统计共聚氨基酸的可注射水溶液形式的组合物
EP17728542.6A EP3463295B1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacidegreffe en bout de chaine
BR112018075250-9A BR112018075250A2 (pt) 2016-06-07 2017-06-07 composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
JP2018564218A JP2019521107A (ja) 2016-06-07 2017-06-07 ヒトグルカゴン及び統計上のコポリアミノ酸を含む注射用溶液の形態の組成物
KR1020197000540A KR20190025905A (ko) 2016-06-07 2017-06-07 인간 글루카곤 및 통계적 코폴리아미노산을 포함하는 주사가능한 수용액 형태의 조성물
JP2018564397A JP2019517560A (ja) 2016-06-07 2017-06-07 ヒトグルカゴン及びコポリアミノ酸を含む注射用溶液の形態の組成物
BR112018075259-2A BR112018075259A2 (pt) 2016-06-07 2017-06-07 composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
CA3026802A CA3026802A1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
AU2017277589A AU2017277589A1 (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
US15/616,627 US10485851B2 (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
SG11201810901VA SG11201810901VA (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
US15/616,542 US10383918B2 (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid
KR1020197000533A KR20190026748A (ko) 2016-06-07 2017-06-07 인간 글루카곤 및 말단-그래프트된 코폴리아미노산을 포함하는 주사가능한 수용액 형태의 조성물
EP17728541.8A EP3463294B1 (fr) 2016-06-07 2017-06-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
AU2017277590A AU2017277590A1 (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
MX2018015070A MX2018015070A (es) 2016-06-07 2017-06-07 Composiciones en forma de solucion acuosa inyectable, que comprende glucagon humano y un co-poliaminoacido injertado en el extremo.
SG11201810939PA SG11201810939PA (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1750221A FR3061660B1 (fr) 2017-01-10 2017-01-10 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR1750221 2017-01-10

Publications (2)

Publication Number Publication Date
FR3061660A1 FR3061660A1 (fr) 2018-07-13
FR3061660B1 true FR3061660B1 (fr) 2019-05-31

Family

ID=59070741

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1750221A Expired - Fee Related FR3061660B1 (fr) 2016-06-07 2017-01-10 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Country Status (1)

Country Link
FR (1) FR3061660B1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) * 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
BR112014016889A8 (pt) * 2012-01-09 2017-07-04 Adocia composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8

Also Published As

Publication number Publication date
FR3061660A1 (fr) 2018-07-13

Similar Documents

Publication Publication Date Title
FR3001896B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
MX2018015070A (es) Composiciones en forma de solucion acuosa inyectable, que comprende glucagon humano y un co-poliaminoacido injertado en el extremo.
SA518400596B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7 يشتمل على أنسولين قاعدي واحد على الأقل تتراوح نقطة (pi) التعادل الكهربائي الخاصة به من 5.8 إلى 8.5، و/أو أنسولين وجبات و/أو هرمون قناة هضمية، وحمض بولي أميني
FR3001895B1 (fr) Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
EA200800233A1 (ru) Композиция иммуноконьюгата
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
MX2021003475A (es) Metodos de purificacion de proteinas.
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
AR100888A1 (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
EP3889185A3 (fr) Composition pour l'amélioration de la solubilité d'une protéine ou peptide à l'aide d'une liaison de fragment d'immunoglobuline fc
MA40709A1 (fr) Dérivé du glucagon à stabilité améliorée
NO20082595L (no) Metastinderivater og deres anvendelse derav
WO2019110797A8 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
SA520412141B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7 يشتمل على إنسولين قاعدي واحد على الأقل يتراوح الخاص به بين 5.8 و8.5 وحمض بولي أمينو مشترك حامل لشحنات pi كربوكسيلات وشقوق غير قابلة للذوبان في الماء
WO2018109588A3 (fr) Composition aqueuse stable d'anticorps anti-c5
EA201891608A1 (ru) Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
RS20080471A (en) Preparing of a pharmaceutical preparation for the treatment of fibrosis using an antagonist of the integrin alpha-4-subunit
FR3061660B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
AR090244A1 (es) Formulacion de anticuerpo anti-selectina p
FR3074683B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
NZ706332A (en) Nail plate hanger with bendable tab
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
TNSN06217A1 (fr) Forme posologique solide

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Search report ready

Effective date: 20180713

PLFP Fee payment

Year of fee payment: 3

ST Notification of lapse

Effective date: 20200906